Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.64 |
| ▸ | CA2 | P00918 | 15/20 | 0.64 |
| ▸ | CA9 | Q16790 | 15/20 | 0.64 |
| ▸ | CA12 | O43570 | 7/20 | 0.64 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.64 |
| ▸ | CA7 | P43166 | 2/20 | 0.62 |
| ▸ | ELF3 | P78545 | 2/20 | 0.58 |
| ▸ | MED23 | Q9ULK4 | 2/20 | 0.58 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12185010 | 0.91 | CA9 (0.70) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21186772 | 0.87 | CA9 (0.65) | CA1CA2CA9CA12CA14 | |
| SCHEMBL14164948 | 0.86 | CA9 (0.72) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21391543 | 0.85 | CA9 (0.69) | CA1CA2CA9CA12CA14 | |
| SCHEMBL15828111 | 0.85 | CA9 (0.83) | CA1CA2CA9CA12CA14 | |
| SCHEMBL12185092 | 0.85 | CA9 (0.73) | CA1CA2CA9CA12CA14 | |
| SCHEMBL22855043 | 0.85 | CA1 (0.70) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21282083 | 0.85 | CA1 (0.70) | CA1CA2CA9CA12CA14 | |
| SCHEMBL17245251 | 0.85 | CA1 (0.70) | CA1CA2CA9CA12CA14 | |
| SCHEMBL13971295 | 0.85 | CA1 (0.64) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | CA1 3676/4885CA2 2790/4885CA9 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.